Hepatitis C: A review and update

Disease-a-Month

Volumn 47, Issue 12, 2001, Pages 610-647

  Bonkovsky, Herbert L ^a   Mehta, Savant ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0035651538     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.109311     Document Type: Article

References (95)

1. Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma: report of 7 cases. JAMA 1943;121:1332.
2. Krugman S, Giles JP, Hammond J. Infectious hepatitis: evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967;200:365-73.
3. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down’s syndrome, leukemia, and hepatitis. Ann Intern Med 1967;66:924-31.
4. Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A: detection by immune electron microscopy of a virus like antigen associated with acute illness. Science 1973;182:1026.
5. Bradley DW, Maynard JE, Popper H, Cook EH, Ebert JW, McCaustland KA, et al. Posttransfusion non-A, non-B hepatitis: physicochemical properties of two distinct agents. J Infect Dis 1983;148:254-65.
6. Bradley DW, McCaustland KA, Cook EH, Schable CA, Ebert JW, Maynard JE. Posttransfusion non-A, non-B hepatitis in chimpanzees: physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology 1985;88:773-9.
7. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
8. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
9. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 1991;88:2451-5.
10. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol 1993;182:329-34.
11. Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992;190:894-9.
12. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasi-species and genotypes. Semin Liver Dis 1995;15:41-63.
13. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes [letter]. Hepatology 1994;19:1321-4.
14. Simmonds P, Smith DB. Investigation of the pattern of diversity of hepatitis C virus in relation to times of transmission. J Viral Hepat 1997;1(Suppl 4)1:69-74.
15. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, et al. The origin of hepatitis C virus genotypes. J Gen Virol 1997;78:321-8.
16. World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rep 1997:341-8.
17. El-Sayed NM, Gomatos PJ, Rodier GR, Wierzba TF, Darwish A, Khashaba S, et al. Seroprevalence survey of Egyptian tourism workers for hepatitis B virus, hepatitis C virus human immunodeficiency virus and Treponema pallidum infections: association of hepatitis C virus infections with specific regions of Egypt. Am J Trop Med Hyg 1996;55:179-184.
18. Nakashima K, Ikematsu H, Hayashi J, Kishihara Y, Mutsutake A, Kashiwagi S. Intrafamilial transmission of hepatitis C virus among the population of an endemic area of Japan. JAMA 1995;274:1459-61.
19. Osella AR, Misciagna G, Leone A, DiLeo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of southern Italy. J Hepatol 1997;27:30-5.
20. Uemra K, Furuta S, Watanabe Y, Watanabe J, Fukuda Y, Takayama T. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. Gastroenterology 1994;106:1596-602.
21. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
22. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:625-55.
23. Vrielink H, Vander Poel CL, Reesink HW, Jaaijer HL, Scholten E, Kremer LCM, et al. Look-back study of infectivity of anti-HCV ELISA-positive blood components. Lancet 1995;345:95-6.
24. Centers for Disease Control and Prevention Public Health Services interagency guidelines for screening blood, plasma, organs, tissue and semen for evidence of Hepatitis B and C. MMWR 1991;40:1-23.
25. Bolumar F, Hernandez-Aguado I, Ferrer L, Ruiz I, Avino M, Rebagliato M. prevalence of antibodies to hepatitis C in a population of intravenous drug users in Valencia, Spain 1990-92. Int J Epidemiol 1996;25:204-9.
26. Allander T, Gruber A, Naghani M, Beyene A, Soderstrom T, Bjorkholm M, et al. Frequent patient-to-patient transmission of hepatitis C virus in a hematology ward. Lancet 1995;345:603-7.
27. Cahn TM, Lok ASF, Cheng IKP, Chan RT. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology 1993;17:5-8.
28. Fabrizi F, Lunghi G, Guarnori I, Raftaele L, Crepalid M, Pagano A, et al. Incidence of seroconversion for hepatitis C virus in chronic hemodialysis patients: a prospective study. Nephrol Dial Transplant 1994;9:1611-5.
29. Esteban JI, Gomez J, Martell M, Cabot B, Quer J, Camps J, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996;334:555-8.
30. Mitsui T, Iwano K, Masuko K, Yamazaki C, Okamoto H, Suda F, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992;16:1109-14.
31. Sartori M, LaTerra G, Aglietta M, Manzin A, Navino C, Verzetti G. Transmission of hepatitis C via blood splash into conjunctiva. Scand J Infect Dis 1993;25:270-1.
32. Lissen E, Alter HJ, Abad MA, Torres Y, Perez-Romero M, Leal M, et al. Hepatitis C virus infection among sexually promiscuous groups and heterosexual partners of hepatitis C virus infected index cases. Eur J Clin Microbiol Infect Dis 1993;12:827-31.
33. Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatol 1997;26(Suppl 1):66S-70S.
34. Gabrielli C, Zannini A, Corradini R, et al. Spread of hepatitis C virus among sexual partners of HCVAb positive intravenous drug users. J Infect Dis 1994; 29:17-22.
35. Buscarini E, Tanzi E, Zanetti AR, Savi E, Sbolli G, Civardi G, et al. High prevalence of antibodies to hepatitis C virus among family members of patients with anti-HCV-positive chronic liver disease. Scand J Gastroenterol 1993;28:343-6.
36. Ohio H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994;330:744-50.
37. Kumar RM, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. J Hepatol 1998;28:191-7.
38. Gordon SC, Patel AH, Kulesza GW, Barnes RE, Silverman AL. Lack of evidence for the heterosexual transmission of hepatitis C. Am J Gastroenterol 1992; 87:1849-51.
39. Wreghitt TG, Gray JJ, Allain J-P, Poulair J, Carson JA, Deaville R, et al. Transmission of hepatitis C virus by organ transplantation in the United Kingdom. J Hepatol 1994;20:768-72.
40. Conrad EV, Gretch DR, Obermeyer RR, Moogk MS, Sayers M, Wilson JJ, et al. Transmission of hepatitis C virus by tissue transplantation. J Bone Joint Surg 1995;77A:214-24.
41. Konig V, Banditz J, Lobock H, Lusebrink R, Neuhaus P, Blumhardt G, et al. Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. Hepatology 1992;16:113743.
42. Sergi C, Jundt K, Seipp S, Goser T, Theilmann L, Otto G, et al. The distribution of HBV, HCV and HGV among livers with fulminant hepatic failure of different aetiology. J Hepatol 1998;29:861-71.
43. Amovoso P, Rapicetta M, Tosti ME, Spada E, Buonocore S, Lettieri G, et al. Correlation between virus genotype and chronicity rate in acute hepatitis C. J Hepatol 1998;28:939-44.
44. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeauz D and the study group for the prevalence and epidemiology of hepatitis C virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 1997;26:485-90.
45. Ray SC, Wang Y, Laeyendecker O, Ticehurst JR, Villano SA, Thanas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999;73:2938-46.
46. Villano SA, Vlahov D, Nelson KE, Cohn S, Themas DL. Persistence of viremia and the importance of long term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-14.
47. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
48. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural history of chronic hepatitis C. Am J Gastroenterol 1993;88:240-3.
49. Yano M, Yatsuhasi H, Inoue O, Inokuchi K, Koga MI. Epidemiology and long-term prognosis of hepatitis C virus infection in Japan. Gut 1993;34(Suppl):S13-S16.
50. Neiderau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998;28:1687-95.
51. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998;28:562-7.
52. Tong MJ, Hu K. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29:1311-6.
53. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis. J Hepatol 1997;27:201-5.
54. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
55. Seeff LB, Miller RN, Rabkin CS, Bushell-Bales Z, Straley-Eason KD, Smook BL, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
56. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C injection in children who underwent cardiac surgery before the implementation of blood donor screening. N Engl J Med 1999;341:866-70.
57. Stetman-Breen CO, Emerson S, Getch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998;32:629-34.
58. Shrasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999;29:1893-9.
59. Obando J, Tortorelli K, Banner B, Stefancyk D, Bonkovsky HL. Iron, the major HFE gene mutation and chronic hepatitis C [abstract]. Gastroenterology 1999;118:A593.
60. Banner BF, Karamitsios N, Smith L, Bonkovsky HL. Enhanced phenotypic expression of alpha 1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C. Am J Gastroenterol 1998;93:1541-5.
61. Clifford BD, Donahue DG, Smith L, Cable E, Luttig B, Manns M, et al. High prevalence of serologic markers of auto-immunity in patients with chronic hepatitis C. Hepatology 1995;21:613-9.
62. Czaja AJ, Carpenter HA, Santrech PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 1995;108:157-64.
63. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R, et al. Latent auto-immune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-7.
64. Shindo M, DiBisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon-a therapy for chronic hepatitis C. Gastroenterology 1992;102:1406-8.
65. Papo T, Marcelin T, Bernau J, Durand F, Poynard T, Benhamou J-P. Auto-immune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992;116:51-3.
66. Georgetson MJ, Yarze JC, Lalos AT, Webster GF, Martin P. Exacerbation of psoriasis due to interferon-a treatment of chronic active hepatitis. Am J Gastroenterol 1993;88:1756-8.
67. Haddad J, Deny P, Munz-Gotheil C, Ambrosini J-C, Trinchet J-C, Pateron D, et al. Lymphocytic sialadenitis of Sjogren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992;339:321-3.
68. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996;24:135-40.
69. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia: a clinical and laboratory study. 2. Cryoglobulins with rheumatoid factor activity. Am J Med 1966;40:837-47.
70. Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 1997;19:111-29.
71. Levey JM, Bjornsson B, Banner B, Kuhns M, Malhotra R, Whitman N, et al. Mixed cryoglobulinemia in chronic hepatitis C infection: a clinico-pathologic analysis of 10 cases and review of recent literature. Medicine 1994;73:53-67.
72. Hahn M, Bonkovsky HL. Disorders of porphyrin metabolism. In: Wu G, Israel J, editors. Diseases of the liver and bile ducts: a practical guide to diagnosis and treatment. Totowa (NJ): Humana Press; 1998. p. 249-72.
73. Bonkovsky HL, Lambrecht RW. Hemochromatosis, iron overload, and porphyria cutanea tarda. In: Barton JC, Edwards CQ, editors. Hemochromatosis. Cambridge (UK): Cambridge University Press; 1999. p. 453-67.
74. Bonkovsky HL, Barnard GF. Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Disease 1998;18:57-65.
75. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, DiBisceglie A, Tattrie C, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661-9.
76. Mignogna MD, Muzio LL, Favia G, Mignogna RE, Carbone R, Bucci E. Oral lichen planus and HCV infection: a clinical evaluation of 263 cases. Int J Dermatol 1998;37:575-8.
77. Jubert C, Pawlotsky JM, Pouget F, Andre C, Deforges D, Bretagne S, et al. Lichen planus and hepatitis C virus-related chronic active hepatitis. Arch Dermatol 1994;130:73-6.
78. Nagao Y, Sata M, Tanikawa K, Itho K, Kameyama T. Lichen planus and hepatitis C virus in the northern region of Japan. Eur J Clin Invest 1995;25:910-4.
79. Grote M, Reichart PA, Berg T, Hops U. Hepatitis C virus (HCV)-infection and oral lichen planus. J Hepatol 1998;29:1034-5.
80. Carson CW, Conn DL, Czaja AJ, Wright TL, Brecher ME. Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol 1993;20:304-9.
81. Kanazawa K, Yaoita H, Murata K, Okamoto H. Association of prurigo with hepatitis C virus infection. Arch Dermatol 1995;131:852-3.
82. Chia SC, Bergasa NV, Kleiner DE, Goodman Z, Herfnagle JH, DiBisceglie AM. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 1998;43: 2177-83.
83. Reichel M, Mauro TM. Urticaria and hepatitis C. Lancet 1990;336:822-3.
84. Domingo P, Ris J, Martinez E, Casas F. Erythema nodosum and hepatitis C. Lancet 1990;336:1377.
85. Antinori S, Esposito R, Aliprandi CA, Tadini G. Erythema multiforme and hepatitis C. Lancet 1991;337:428.
86. Neri S, Racih C, D’Angelo G, Ierna D, Bruno CM. Hyde’s prurigo nodularis and chronic HCV hepatitis. J Hepatol 1998;28:161-4.
87. Darouti ME, Ela ME. Nerolytic acral erythema: a cutaneous marker of hepatitis C. Int J Dermatol 1996;35:252-6.
88. Sookoian S, Neglia V, Castano G, Frider B, Kien MC, Chohuda E, et al. High prevalence of cutaneous reactions to interferon alpha plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol 1999;135:1000-1.
89. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
90. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
91. Davis GL, Estebon-Mur R, Rustgi V, Hoefs J. Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
92. Bonkovsky HL, Stefancyk D, LeClair P, Zucker G, Israel J, Stagias J, et al. Low doses (600 mg/d) of ribavirin are superior to high doses (1000-1200 mg/d) with interferon for chronic hepatitis C: results of a controlled, randomized, multi-center trial [abstract]. Hepatology 1999;30:265A.
93. Bonkovsky HL. Therapy of hepatitis C: other options. Hepatology 1997;26(Suppl 1):143S-151S.
94. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997;25:759-68.
95. Fontana R, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, et al. Iron reduction prior to and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-6.